Form 8-K - Current report:
SEC Accession No. 0001628280-26-017230
Filing Date
2026-03-12
Accepted
2026-03-12 16:07:14
Documents
14
Period of Report
2026-03-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K allo-20260312.htm   iXBRL 8-K 26137
2 EX-99.1 allo-20260312xexx9912025pr.htm EX-99.1 66198
6 g725933allogenea06a.jpg GRAPHIC 7772
  Complete submission text file 0001628280-26-017230.txt   229665

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20260312.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20260312_lab.xml EX-101.LAB 21615
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20260312_pre.xml EX-101.PRE 12595
16 EXTRACTED XBRL INSTANCE DOCUMENT allo-20260312_htm.xml XML 2957
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 26747686
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)